This content is restricted.
Brief
The European Commission imposed a fine of €462.6 million on Teva Pharmaceutical Industries for abusing its dominant position in the European Union market for its multiple sclerosis drug, Copaxone. The sanction was due to Teva's strategic misuse of patent laws to delay competition and a targeted disparagement campaign against a competitor, impacting treatment choice and public health costs.
Highlights content goes here...
This content is restricted.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested